Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
4.525
-0.205 (-4.33%)
Sep 10, 2026, 1:02 PM EDT - Market open
Cytek Biosciences Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 588 | 646 | 836 | 1,236 | 1,377 | 2,182 | |
Market Cap Growth | 15.00% | -22.76% | -32.38% | -10.21% | -36.91% | - |
Enterprise Value | 353 | 409 | 573 | 963 | 1,051 | 1,806 |
Last Close Price | 4.73 | 5.05 | 6.49 | 9.12 | 10.21 | 16.32 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 534.49 | 41969.36 |
Forward PE | - | 89.56 | 26.14 | 245.06 | 44.39 | 152.95 |
PS Ratio | 2.85 | 3.21 | 4.17 | 6.41 | 8.39 | 17.06 |
PB Ratio | 1.91 | 1.89 | 2.11 | 3.15 | 3.24 | 5.38 |
P/TBV Ratio | 2.03 | 2.10 | 2.33 | 3.49 | 3.35 | 5.59 |
P/FCF Ratio | - | - | 38.25 | 1952.94 | - | 8204.54 |
P/OCF Ratio | - | - | 32.94 | 234.09 | - | 471.36 |
PEG Ratio | - | 1.34 | 1.34 | 1.34 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.72 | 2.03 | 2.86 | 4.99 | 6.41 | 14.12 |
EV/EBITDA Ratio | - | - | - | - | 1527.81 | 173.67 |
EV/EBIT Ratio | - | - | - | - | - | 197.22 |
EV/FCF Ratio | - | - | 26.21 | 1522.10 | - | 6789.29 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.08 | 0.07 | 0.04 | 0.04 | 0.04 | - |
Debt / EBITDA Ratio | - | - | - | - | 4.23 | - |
Debt / FCF Ratio | - | - | 0.78 | 22.33 | - | - |
Net Debt / Equity Ratio | -0.73 | -0.70 | -0.66 | -0.63 | -0.76 | -0.90 |
Net Debt / EBITDA Ratio | 5.92 | 7.25 | 19.60 | 11.39 | -469.56 | -35.06 |
Net Debt / FCF Ratio | 19.50 | 27.11 | -11.94 | -392.22 | 14.70 | -1370.74 |
Asset Turnover | 0.44 | 0.42 | 0.40 | 0.38 | 0.33 | 0.38 |
Inventory Turnover | 1.93 | 2.09 | 1.70 | 1.52 | 1.55 | 1.76 |
Quick Ratio | 3.72 | 4.29 | 5.00 | 5.67 | 7.99 | 11.88 |
Current Ratio | 4.48 | 5.04 | 5.86 | 6.97 | 9.26 | 13.01 |
Return on Equity (ROE) | -23.04% | -18.05% | -1.53% | -2.97% | 0.60% | 1.04% |
Return on Assets (ROA) | -6.31% | -5.25% | -2.58% | -3.43% | -0.23% | 1.68% |
Return on Invested Capital (ROIC) | -52.92% | -33.82% | -14.68% | -22.52% | -2.52% | 16.50% |
Return on Capital Employed (ROCE) | -13.10% | -10.50% | -4.80% | -6.40% | -0.40% | 2.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -13.65% | -10.30% | -0.72% | -0.98% | 0.19% | 0.14% |
FCF Yield | -2.05% | -1.36% | 2.61% | 0.05% | -1.60% | 0.01% |
Buyback Yield / Dilution | 0.28% | 2.19% | 3.45% | 2.37% | -69.93% | -150.13% |